These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17337182)

  • 101. Bioactivities of a series of phosphodiesterase type 5 (PDE-5) inhibitors as modelled by MIA-QSAR.
    Antunes JE; Freitas MP; Rittner R
    Eur J Med Chem; 2008 Aug; 43(8):1632-8. PubMed ID: 18045743
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
    Reddy GL; Dar MI; Hudwekar AD; Mahajan P; Nargotra A; Baba AM; Nandi U; Wazir P; Singh G; Vishwakarma RA; Syed SH; Sawant SD
    Bioorg Chem; 2019 Aug; 89():103022. PubMed ID: 31181491
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Role of sildenafil in neurological disorders.
    Farooq MU; Naravetla B; Moore PW; Majid A; Gupta R; Kassab MY
    Clin Neuropharmacol; 2008; 31(6):353-62. PubMed ID: 19050413
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Visual side effects associated with erectile dysfunction agents.
    Fraunfelder FW
    Am J Ophthalmol; 2005 Oct; 140(4):723-4. PubMed ID: 16226525
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
    Francis SH; Morris GZ; Corbin JD
    Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
    [TBL] [Abstract][Full Text] [Related]  

  • 106. [PDE5 inhibitors and satisfaction of patients with erectile dysfunction].
    Cour F
    Prog Urol; 2008 Sep; 18(8):542. PubMed ID: 18760745
    [No Abstract]   [Full Text] [Related]  

  • 107. Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors.
    Ho GD; Silverman L; Bercovici A; Puchalski C; Tulshian D; Xia Y; Czarniecki M; Green M; Cleven R; Zhang H; Fawzi A
    Bioorg Med Chem Lett; 1999 Jan; 9(1):7-12. PubMed ID: 9990447
    [TBL] [Abstract][Full Text] [Related]  

  • 108. PDE5 inhibitors: is there more to come besides erectile dysfunction?
    Stief C
    Eur Urol; 2007 Oct; 52(4):943-4. PubMed ID: 17683851
    [No Abstract]   [Full Text] [Related]  

  • 109. [Phosphodiesterase inhibitors in clinical practice. The present and the future. Part II].
    Baksheev BI; Kolomiets NM
    Klin Med (Mosk); 2007; 85(4):4-11. PubMed ID: 17564028
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
    Pitts WJ; Vaccaro W; Huynh T; Leftheris K; Roberge JY; Barbosa J; Guo J; Brown B; Watson A; Donaldson K; Starling GC; Kiener PA; Poss MA; Dodd JH; Barrish JC
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2955-8. PubMed ID: 15125967
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction.
    Hudwekar AD; Kotwal P; Dar MI; Balgotra S; Dogra A; Kour J; Chobe SS; Nandi U; Hussain Syed S; Sawant SD
    Chem Biodivers; 2023 Apr; 20(4):e202200707. PubMed ID: 36915218
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Synthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile dysfunction.
    Flores Toque HA; Priviero FB; Teixeira CE; Perissutti E; Fiorino F; Severino B; Frecentese F; Lorenzetti R; Baracat JS; Santagada V; Caliendo G; Antunes E; De Nucci G
    J Med Chem; 2008 May; 51(9):2807-15. PubMed ID: 18393409
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction.
    Thurtell MJ; Tomsak RL
    Int J Impot Res; 2008; 20(6):537-43. PubMed ID: 18528398
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts.
    Keravis T; Thaseldar-Roumié R; Lugnier C
    Methods Mol Biol; 2005; 307():63-74. PubMed ID: 15988055
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation.
    Sakamoto T; Koga Y; Hikota M; Matsuki K; Murakami M; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5175-80. PubMed ID: 25442307
    [TBL] [Abstract][Full Text] [Related]  

  • 116. 8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.
    Sakamoto T; Koga Y; Hikota M; Matsuki K; Mochida H; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1431-5. PubMed ID: 25754491
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Analysis of dimerization determinants of PDE6 catalytic subunits.
    Muradov KG; Boyd KK; Artemyev NO
    Methods Mol Biol; 2005; 307():263-75. PubMed ID: 15988069
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog.
    Walker DK; Beaumont KC; Comby P; Evans KM; Gedge JI; Halliday RC; Roffey SJ; Wright PA
    Xenobiotica; 2001; 31(8-9):651-64. PubMed ID: 11569531
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Design of second generation phosphodiesterase 5 inhibitors.
    Palmer MJ; Bell AS; Fox DN; Brown DG
    Curr Top Med Chem; 2007; 7(4):405-19. PubMed ID: 17305582
    [TBL] [Abstract][Full Text] [Related]  

  • 120. PDE 5 inhibitors and HIV risk: current concepts and controversies.
    Jackson G
    Int J Clin Pract; 2005 Nov; 59(11):1247-8. PubMed ID: 16236072
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.